|Videos|May 26, 2022
Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data
Author(s)Brian Shimkus, MD, Tom Powles, MBBS, MRCP, MD
Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.
Advertisement
Episodes in this series
Advertisement
Related to this article
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5